Leukeran (Chlorambucil)

Chlorambucil alkylates DNA, creating cross‑links that prevent DNA replication and transcription. This damage triggers cell‑cycle arrest and programmed cell death, especially in rapidly dividing cancer cells, thereby reducing tumor burden in hematologic malignancies.

The dosing regimen for Leukeran is individualized and set by the prescribing oncologist or hematologist based on the patient’s specific condition, disease stage, and tolerance. Patients should follow the prescriber’s instructions and not alter the dose without medical guidance.

Safety data for chlorambucil during pregnancy and lactation are limited, and the drug may pose risks to the fetus or infant. It is generally avoided in pregnant or nursing women unless the potential benefit outweighs the risk, and alternative therapies are considered.

To order Leukeran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Leukeran belongs to the alkylating agent class, similar to cyclophosphamide and melphalan. Compared with cyclophosphamide, chlorambucil is administered orally and often has a milder toxicity profile, but both share risks of bone‑marrow suppression and secondary malignancies. Choice depends on disease specifics, patient tolerance and treatment protocol.

Leukeran tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Leukeran is taken orally as a tablet with a full glass of water, usually on an empty stomach unless directed otherwise by the prescriber. The exact timing and frequency are determined by the treating physician based on the therapeutic plan.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, opportunistic infections, secondary cancers such as acute leukemia, pulmonary toxicity, and severe allergic reactions. Patients should report signs of infection, unusual bleeding, persistent fever, or respiratory symptoms promptly.

Leukeran is contraindicated in patients with known hypersensitivity to chlorambucil or other alkylating agents, those with severe bone‑marrow suppression, active uncontrolled infections, or pregnant women unless the benefits outweigh the risks. It should also be used with caution in individuals with significant liver impairment.